Use of Continuous Subcutaneous Growth Hormone‐Releasing Hormone (GHRH (1–29)NH₂) Infusions to Augment Growth Hormone Secretion and to Promote Growth

Brain, C., Hindmarsh, P.C., Pringle, P.J. and Brook, C.G.D. (Endocrine Unit, the Middlesex Hospital, London, UK). Use of continuous subcutaneous growth hormone‐releasing hormone (GHRH (1–29)NH 2 ) infusions to augment growth hormone secretion and to promote growth. Acta Paediatr Scand [Suppl] 349: 109, 1989. It has previously been shown that an 8‐day continuous subcutaneous infusion of GHRH (1–29)NH 2 in adult males augments growth hormone (GH) secretion with no evidence of desensitization of the response. The present report details the results of treatment with continuous subcutaneous infusions of CHRH (1–29)NH 2 in eight children aged 6–9 years with partial GH insufficiency. All the children showed augmentation of GH secretion and an increase in growth velocity after 3 and 6 months of therapy.